
Venture capital
Aditum Bio
Aditum Bio is a biotech venture capital firm that acquires clinic-ready drug candidates and forms and operates portfolio companies to advance them through early clinical trials.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is Aditum Bio right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (SEC adviser filings). Values are the gross assets each filing reports, not fund sizes.
Latest investments
BetaRounds Aditum Bio joined, from press and the firm’s own posts.
1 round in the last 12 months
Round sizes, Aditum Bio’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company Aditum Bio backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet Aditum Bio
Events where Aditum Bio’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
Aditum Bio is based in Oakland, United States. It also has an office in Cambridge.
3 fund vehicles are on public registers (SEC adviser filings), including ADITUM BIO FUND 3, L.P., ADITUM BIO FUND 2, L.P. and ADITUM BIO FUND 1, L.P.
Sectors: Biotech, Life sciences. From the firm’s own website.
Focuses on the translational stage of drug development, acquiring promising clinic-ready therapies for underserved patient populations. In-house R&D experts and a lean operating model speed company formation and move candidates into Phase 2 trials, using digital tools to run trials efficiently and cut costs. From the firm’s own website.
Aditum Bio lists 5 portfolio companies on its website: Kalexo Bio, Versanis, Oblenio Bio, Vitalli Bio and Trames Bio.
Know before Aditum Bio’s next round is announced.
PRO tracks Aditum Bio’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.